Industry M&A Weekly: McKesson's $2.25B Precision Buy, Roche's $2.3B Hanmi License, and Three More

Five transactions met the issue's inclusion bar between August 19 and August 26, 2026 (UTC). The largest cash acquisitions are McKesson's roughly $2.25 billion purchase of clinical-research and biopharma commercialization firm Precision Medicine Group and Munich Re's $575 million enterprise-value deal for cyber insurtech At-Bay. Two biotech licenses put most of the headline total into milestones and royalties: Roche-Genentech's up-to-$2.3 billion Hanmi obesity rights package and SK Biopharmaceuticals' up-to-$795 million Biohaven epilepsy platform deal. Ambros Therapeutics is using a reverse merger with Nasdaq-listed Werewolf Therapeutics plus a concurrent $150 million private placement to fund a Phase 3 rare-pain program. 12345

The common question is what the buyer is paying to control. In healthcare services and insurance, the answer is an operating platform already wired into trial execution, drug launch, or SME cyber underwriting. In biotech licensing, buyers are purchasing a clinical mechanism and a development handoff while leaving most of the price contingent on later evidence.

McKesson agreed to acquire privately held Precision Medicine Group for about $2.25 billion. After closing, the business will sit inside McKesson's Oncology & Multispecialty segment. The companies did not publish a close date; the deal is subject to customary closing conditions and regulatory clearances. 1

Precision Medicine Group, based in Bethesda, Maryland, sells integrated services that take biopharma programs from molecule toward market: biomarker intelligence, laboratory testing, a global clinical research organization, market-access consulting, and commercialization support. McKesson CEO Brian Tyler said the acquisition would enhance clinical research and commercialization services, strengthen trial execution, and broaden the company's clinical offerings. 17

The strategic context is McKesson's multi-year shift toward higher-growth oncology and specialty services. Reuters reported that Oncology & Multispecialty revenue rose 33% to $14.2 billion in the first quarter of fiscal 2026, helped by earlier specialty investments, while McKesson has also sold or prepared non-core units for exit. Leerink Partners analyst Michael Cherny told Reuters the purchase equals a little more than 2% of McKesson's market capitalization and is therefore a tuck-in rather than a balance-sheet reset. 7

The asset being bought is a services stack that already sits beside biopharma sponsors through trial, lab, and launch work. McKesson is paying for that workflow position, not for a single drug or a distribution-only footprint.

Hanmi Pharm licensed HM17321, a proprietary urocortin-2 analog, to Genentech, a member of the Roche Group, for development, manufacturing, and commercialization worldwide outside South Korea. Genentech will pay $190 million up front. Including development, regulatory, and commercial milestones, the package can reach about $2.3 billion, plus tiered royalties on future net sales. 3

HM17321 is designed for chronic weight management and related conditions such as type 2 diabetes and cardiovascular disease. Unlike GLP-1 incretin drugs that reduce weight partly by losing lean tissue, the candidate is meant to promote fat loss while preserving lean body mass. Hanmi received U.S. FDA IND clearance in November 2025 and is running a Phase 1 study in healthy volunteers and people with obesity. Hanmi will finish that trial; Genentech takes over from Phase 2. 36

Roche's stated rationale is to build a cardiometabolic portfolio that goes beyond pure weight reduction. BioPharma Dive noted that Roche is still behind obesity market leaders Lilly and Novo Nordisk on incretin drugs, and that lean-mass-sparing approaches are a next wave investors and physicians are watching. The companies are also racing Denmark's Gubra, which started a Phase 1/2 urocortin-2 trial in July. 6

This is a rights transaction, not a purchase of Hanmi. Roche-Genentech gains a defined clinical mechanism and a development handoff after Phase 1, while most of the $2.3 billion total remains contingent on later trial, approval, and commercial outcomes.

SK Biopharmaceuticals agreed to take an exclusive worldwide license to Biohaven's Kv7 ion-channel platform, led by opakalim (BHV-7000). Biohaven will receive $400 million in near-term cash—$350 million at closing and $50 million in 2027—plus up to $150 million in development and regulatory milestones. The companies describe total platform payments of up to $795 million, with tiered U.S. royalties from the mid-teens to low twenties and mid-single-digit royalties outside the United States. Closing is subject to Hart-Scott-Rodino review and other customary conditions. 4

Opakalim is a selective Kv7.2/7.3 potassium-channel activator in Phase 2/3 development for focal epilepsy. Biohaven is running two randomized Phase 2/3 adjunctive studies, with RISE3 topline results expected in the second half of 2026. The candidate is designed as a once-daily oral therapy without titration and with a lower burden of central-nervous-system side effects than many antiseizure medicines. Opakalim has been studied in more than 1,200 participants. 4

SK Biopharmaceuticals is the company behind XCOPRI (cenobamate) and operates a U.S. neurology field force of more than 150 people through SK Life Science. Biohaven said the partnership gives opakalim a commercial path without Biohaven building its own epilepsy sales infrastructure, while SK assumes ongoing Kv7 program costs and specified Knopp Biosciences obligations of up to $245 million plus mid-single-digit royalties. 4

The structure separates three layers of value: cash that strengthens Biohaven's balance sheet now, milestones tied to development and approval, and royalties if the drug sells. SK is buying a late-stage mechanism plus the commercial right to place it through an existing epilepsy franchise.

Munich Re agreed to acquire At-Bay at an enterprise value of $575 million. Closing is expected in the first quarter of 2027, subject to regulatory approvals and other customary conditions. The business will be overseen by Hartford Steam Boiler (HSB), Munich Re's specialty and cyber-focused arm. 28

At-Bay, founded in 2017, sells integrated cyber insurance and cybersecurity to U.S. small and medium-sized enterprises. As of year-end 2025 it reported $278 million in gross written premiums under U.S. GAAP, plus $23 million in cyber fee-service revenue, and employed about 280 people in the United States and Israel. HSB has been a main strategic partner since At-Bay's founding. At-Bay's platform monitors and reduces insured cyber risk across the policy lifecycle and feeds underwriting data back into pricing. 2

Munich Re board member Mike Kerner said At-Bay would become part of Munich Re Specialty's cyber offering and an earnings-growth driver over time. HSB CEO Jeffrey O'Shaughnessy framed the deal as a move toward vertically integrated insurer-security platforms rather than standalone cyber coverage alone. 2

The buyer already reinsures or partners into cyber risk; the acquisition converts that relationship into ownership of underwriting data, security tooling, and the SME distribution layer. Enterprise value of $575 million is the disclosed headline; the release does not break out equity value versus net debt.

Werewolf Therapeutics and Ambros Therapeutics signed a definitive all-stock merger agreement. The combined company will operate as Ambros Therapeutics, headquartered in San Diego, and is expected to trade on Nasdaq as AMBX. The exchange ratio uses an implied value of $500 million for Ambros before the concurrent financing and $47.5 million for Werewolf. Pre-merger Ambros holders are expected to own about 71.7%, private-placement investors about 21.5%, and pre-merger Werewolf holders about 6.8%, subject to Werewolf net-cash adjustments. Closing is expected by the first quarter of 2027. 59

In parallel, the companies secured an oversubscribed $150 million private placement co-led by RA Capital Management and Janus Henderson Investors. Ambros expects the combined cash runway to reach into the first half of 2029, covering Phase 3 topline results expected in 2028 and a planned NDA submission. Werewolf shareholders outside the private placement will also receive a contingent value right on proceeds from any sale of Werewolf's legacy assets. 5

Ambros's lead program is neridronate, an aminobisphosphonate already used in Italy for conditions including CRPS-1. The pivotal CRPS-RISE Phase 3 trial is enrolling about 270 people with warm CRPS-1 and a positive triple-phase bone scan. Patients receive four intravenous infusions over 10 days; the primary endpoint is change in pain intensity at week 12. Ambros estimates 50,000 to 70,000 newly diagnosed U.S. CRPS-1 patients a year and notes there is no FDA-approved therapy. The FDA has granted Breakthrough Therapy, Fast Track, and Orphan Drug designations. 59

Werewolf had been seeking strategic alternatives after cash runway shortened and after selling other assets. The reverse merger is a capital-markets path rather than a classic strategic acquisition: Ambros buys a public listing and a financing syndicate, while Werewolf holders keep a small equity stake and a CVR on leftover programs. 9

McKesson is buying a CRO-plus-commercialization stack that already works for biopharma sponsors. Munich Re is buying an insurer-security platform that already underwrites and monitors SME cyber risk. SK Biopharmaceuticals is licensing a Phase 2/3 epilepsy candidate into the commercial organization that launched XCOPRI. In each case the target already sits between the customer and a fragmented supply of trials, security tools, or antiseizure options. 124

The strategic value is the installed position. Capital, distribution, or reinsurance capacity can be added after closing; rebuilding the data, relationships, and operating habits that make the platform useful would take longer.

Both large biotech licenses split control today from final payment. Roche-Genentech pays Hanmi $190 million now against a package that can reach about $2.3 billion plus royalties. SK Biopharmaceuticals pays Biohaven $400 million near term against up to $795 million in platform payments, then royalties if opakalim sells. 34

The structures match different stages of risk. HM17321 is still in Phase 1; opakalim is in Phase 2/3 with a near-term data read. Buyers gain the right to develop and commercialize before the final clinical verdict, while sellers receive more only if the programs clear later gates.

Ambros is not selling to a strategic acquirer. It is combining with a cash-constrained public biotech, raising $150 million from specialist healthcare funds, and aiming a single pivotal trial at an orphan indication with no approved drug. The $500 million pre-PIPE Ambros valuation and the small Werewolf residual stake show how reverse-merger math prices the private pipeline higher than the public shell. 5

For deal readers, the useful comparison is control versus cash. McKesson and Munich Re buy whole companies for fixed enterprise prices. Roche and SK buy rights with large contingent tails. Ambros buys a listing and a syndicate, and the $150 million PIPE is the hard cash that funds the Phase 3.

This issue covers transaction disclosures from August 19 through August 26, 2026 (UTC). Five deals met the minimum count and had accessible evidence for value, structure, buyer rationale, and target or asset background. Munich Re/At-Bay was announced on August 19, before the prior issue's publication that same morning, and was not covered there; it is included here. Biotech and licensing totals separate near-term cash from milestones and royalties; they are maximum economics rather than cash paid at signing. Ambros/Werewolf is an all-stock reverse merger plus financing, so the $500 million Ambros valuation and the $150 million PIPE are separate figures.

Several candidates were screened and left out because terms or status did not clear the bar: Gamma's acquisition of design startup Lica had no disclosed price; Hugging Face acquisition talks at a reported $13 billion valuation have not produced a signed deal; T. Rowe Price's agreement to buy F/m Investments disclosed no economics; and Vista's possible sale of Allvue remains exploratory. No deal announced after the August 26 publication cutoff is included.